Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function

Kenji Takeyoshi,1,2 Masatake Kurita,1–3 Satoshi Nishino,2,3 Mika Teranishi,1 Yukio Numata,2 Tadahiro Sato,2 Yoshiro Okubo11Department of Psychiatry and Behavioral Science, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 2Sato Hospital, Koutokukai, Nanyo, Yamagata, 3De...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeyoshi K, Kurita M, Nishino S, Teranishi M, Numata Y, Sato T, Okubo Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	herbal medicine MHPG homovanillic acid HVA noradrenaline BPSD Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8d8f0286fefe4a3d920c5cd3a4c2d088
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d8f0286fefe4a3d920c5cd3a4c2d088
record_format	dspace
spelling	oai:doaj.org-article:8d8f0286fefe4a3d920c5cd3a4c2d0882021-12-02T04:59:58ZYokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function1178-2021https://doaj.org/article/8d8f0286fefe4a3d920c5cd3a4c2d0882016-03-01T00:00:00Zhttps://www.dovepress.com/yokukansan-improves-behavioral-and-psychological-symptoms-of-dementia--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Kenji Takeyoshi,1,2 Masatake Kurita,1–3 Satoshi Nishino,2,3 Mika Teranishi,1 Yukio Numata,2 Tadahiro Sato,2 Yoshiro Okubo11Department of Psychiatry and Behavioral Science, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 2Sato Hospital, Koutokukai, Nanyo, Yamagata, 3Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, JapanAbstract: Although three drugs, risperidone, yokukansan, and fluvoxamine, have shown equal efficacy in treating behavioral and psychological symptoms of dementia (BPSD) in our previous study, their mechanisms of action are different from one another. Monoamines have attracted attention for their key roles in mediating several behavioral symptoms or psychological symptoms through synaptic signaling. We aimed to clarify the monoamines changed by treatment with each drug in patients with BPSD. The main purpose of this study was to determine whether plasma levels of catecholamine metabolites are correlated with pharmacological treatments. This was an 8-week, rater-blinded, randomized, flexible-dose, triple-group trial. In total, 90 subjects were recruited and subsequently three different drugs were allocated to 82 inpatients with BPSD. We examined BPSD data from patients who completed 8 weeks of treatment. Eventually, we analyzed 42 patients (yokukansan: 17; risperidone: 9; fluvoxamine: 16). Homovanillic acid, a metabolite of dopamine, and 3-methoxy-4-hydroxyphenylglycol, a metabolite of noradrenaline, in their plasma were analyzed by high-performance liquid chromatography with electrochemical detection. All three drugs showed equal significant efficacy between baseline and study endpoint. By contrast, biomarkers showed mutually different changes. Patients in the yokukansan group had significantly decreased plasma homovanillic acid levels from baseline. Conversely, patients in the risperidone and fluvoxamine groups exhibited no significant changes in plasma homovanillic acid levels from baseline. Yokukansan contains geissoschizine methyl ether, which is known to have a partial agonist effect on dopamine D2 receptors. An improvement in BPSD condition with the intake of yokukansan is suggested to occur through a suppressed dopaminergic function, which is similar to the effect of aripiprazole.Keywords: herbal medicine, MHPG, homovanillic acid, HVA, noradrenaline, BPSDTakeyoshi KKurita MNishino STeranishi MNumata YSato TOkubo YDove Medical Pressarticleherbal medicineMHPGhomovanillic acidHVAnoradrenalineBPSDNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 641-649 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	herbal medicine MHPG homovanillic acid HVA noradrenaline BPSD Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	herbal medicine MHPG homovanillic acid HVA noradrenaline BPSD Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Takeyoshi K Kurita M Nishino S Teranishi M Numata Y Sato T Okubo Y Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
description	Kenji Takeyoshi,1,2 Masatake Kurita,1–3 Satoshi Nishino,2,3 Mika Teranishi,1 Yukio Numata,2 Tadahiro Sato,2 Yoshiro Okubo11Department of Psychiatry and Behavioral Science, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 2Sato Hospital, Koutokukai, Nanyo, Yamagata, 3Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, JapanAbstract: Although three drugs, risperidone, yokukansan, and fluvoxamine, have shown equal efficacy in treating behavioral and psychological symptoms of dementia (BPSD) in our previous study, their mechanisms of action are different from one another. Monoamines have attracted attention for their key roles in mediating several behavioral symptoms or psychological symptoms through synaptic signaling. We aimed to clarify the monoamines changed by treatment with each drug in patients with BPSD. The main purpose of this study was to determine whether plasma levels of catecholamine metabolites are correlated with pharmacological treatments. This was an 8-week, rater-blinded, randomized, flexible-dose, triple-group trial. In total, 90 subjects were recruited and subsequently three different drugs were allocated to 82 inpatients with BPSD. We examined BPSD data from patients who completed 8 weeks of treatment. Eventually, we analyzed 42 patients (yokukansan: 17; risperidone: 9; fluvoxamine: 16). Homovanillic acid, a metabolite of dopamine, and 3-methoxy-4-hydroxyphenylglycol, a metabolite of noradrenaline, in their plasma were analyzed by high-performance liquid chromatography with electrochemical detection. All three drugs showed equal significant efficacy between baseline and study endpoint. By contrast, biomarkers showed mutually different changes. Patients in the yokukansan group had significantly decreased plasma homovanillic acid levels from baseline. Conversely, patients in the risperidone and fluvoxamine groups exhibited no significant changes in plasma homovanillic acid levels from baseline. Yokukansan contains geissoschizine methyl ether, which is known to have a partial agonist effect on dopamine D2 receptors. An improvement in BPSD condition with the intake of yokukansan is suggested to occur through a suppressed dopaminergic function, which is similar to the effect of aripiprazole.Keywords: herbal medicine, MHPG, homovanillic acid, HVA, noradrenaline, BPSD
format	article
author	Takeyoshi K Kurita M Nishino S Teranishi M Numata Y Sato T Okubo Y
author_facet	Takeyoshi K Kurita M Nishino S Teranishi M Numata Y Sato T Okubo Y
author_sort	Takeyoshi K
title	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
title_short	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
title_full	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
title_fullStr	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
title_full_unstemmed	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
title_sort	yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/8d8f0286fefe4a3d920c5cd3a4c2d088
work_keys_str_mv	AT takeyoshik yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction AT kuritam yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction AT nishinos yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction AT teranishim yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction AT numatay yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction AT satot yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction AT okuboy yokukansanimprovesbehavioralandpsychologicalsymptomsofdementiabysuppressingdopaminergicfunction
_version_	1718400901569314816

Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function

Ejemplares similares